Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-May 2006. Module: SNOMED CT United Kingdom drug extension module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 32336101000001114 | Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) (product) | en | Fully specified name | Active | Only initial character case insensitive | SNOMED CT United Kingdom drug extension module |
| 43168501000001113 | Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (Imported (Switzerland)) | en | Synonym | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has NHS dm+d (dictionary of medicines and devices) controlled drug category | Controlled drug category No Controlled Drug Status | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator | NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction imported | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has excipient | Excipient not declared | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Is a | Bupivacaine 25mg/5ml / Adrenaline 25micrograms/5ml (1 in 200,000) solution for injection ampoules | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has active ingredient | Epinephrine bitartrate | false | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has active ingredient | Bupivacaine hydrochloride anhydrous | false | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | VMP prescribing status (attribute) | VMP valid as a prescribable product | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | VMP non-availability indicator | Available | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has manufactured dose form | Conventional release solution for injection | false | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has NHS dm+d (dictionary of medicines and devices) basis of strength substance | Epinephrine | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has specific active ingredient | Bupivacaine hydrochloride anhydrous | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has specific active ingredient | Epinephrine bitartrate | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has active ingredient | Bupivacaine | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has active ingredient | Epinephrine | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has dispensed dose form | Conventional release solution for injection | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has manufactured dose form | Parenteral dose form | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Is a | Actual medicinal product | true | Inferred relationship | Existential restriction modifier | ||
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Has basis of strength substance | Epinephrine | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) 1 ampoule | Is pack of | False | Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Inferred relationship | Existential restriction modifier | |
| Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) 1 ampoule | Has AMP | True | Carbostesin-adrenaline 0.5% / 25micrograms/5ml (1 in 200,000) solution for injection ampoules (AstraZeneca) | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets
FHIR